Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow NEUP by emailGet an email when NEUP pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about NEUP, unsubscribe in one click. Privacy
📣 What NEUP Says Is Next
H1 27 · “Additional expansion potential to $6-9bn in peak sales in the neoadjuvant/adjuvant setting − Phase 2 initiation in neoadjuvant/adjuvant melanoma expected in H1 27 Defined regulatory path to accelerated approval”
Company press release, Jul 24, 2026 · SEC filing
H2 2026 · “Phase 3 initiation in the U.S. anticipated in H2 2026”
Company press release, Jul 24, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full NEUP picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NEUP and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.